After Leerink Partners and Merrill Lynch gave Exact Sciences (NASDAQ: EXAS) a Buy rating last month, the company received another Buy, this time from Robert W. Baird. Analyst Catherine Schulte reiterated a Buy rating on Exact Sciences today and set a price target of $65. The company’s shares opened today at $48.26.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of 26.0% and a 79.2% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Oxford Immunotec, NanoString Tech, and Thermo Fisher.
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $68, which is a 40.9% upside from current levels. In a report issued on July 19, Leerink Partners also maintained a Buy rating on the stock with a $76 price target.
.
See today’s analyst top recommended stocks >>
Based on Exact Sciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $36.39 million. In comparison, last year the company had a GAAP net loss of $30.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It has an intellectual property, which protects its non invasive, molecular screening technology for the detection of colorectal cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
